Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye
To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may...
Saved in:
Published in | ACS applied bio materials Vol. 4; no. 2; pp. 1461 - 1469 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
15.02.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may lead to local side effects. The present study attempts to develop a dosage-controllable drug delivery implant that consists of a nanoporous biodegradable PLGA capsule and light-activated liposomes. Controllable drug release from the implant was achieved using a pulsed near-infrared (NIR) laser both in vitro and in vivo. The in vitro drug release kinetics from two different initial dose implants, 1000 and 500 μg, was analyzed by fitting zero-order and first-order kinetics, as well as the Korsmeyer–Peppas and Higuchi models. The 1000 and 500 μg implants fit the first-order and zero-order kinetics model, respectively, the best. The multiple drug releases in the vitreous were determined by an in vivo fluorimeter, which was consistent with the in vitro data. The dose released was also clinically relevant. Histology and optical and ultrasound imaging data showed no abnormality in the eyes received implant treatment, suggesting that the drug delivery system was safe to the retina. This on-demand dose-controllable drug delivery system could be potentially used for long-term posterior eye disease treatment to avoid frequent invasive injections. |
---|---|
AbstractList | To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care. Sustained-release drug implants often involve burst release of the drugs and the dosage from the implants cannot be controlled after implantation, which may lead to local side effects. The present study attempts to develop a dosage-controllable drug delivery implant that consists of a nanoporous biodegradable PLGA capsule and light-activated liposomes. Controllable drug release from the implant was achieved using a pulsed near-infrared (NIR) laser both in vitro and in vivo. The in vitro drug release kinetics from two different initial dose implants, 1000 and 500 μg, was analyzed by fitting zero-order and first-order kinetics, as well as the Korsmeyer-Peppas and Higuchi models. The 1000 and 500 μg implants fit the first-order and zero-order kinetics model, respectively, the best. The multiple drug releases in the vitreous were determined by an in vivo fluorimeter, which was consistent with the in vitro data. The dose released was also clinically relevant. Histology and optical and ultrasound imaging data showed no abnormality in the eyes received implant treatment, suggesting that the drug delivery system was safe to the retina. This on-demand dose-controllable drug delivery system could be potentially used for long-term posterior eye disease treatment to avoid frequent invasive injections. |
Author | Park, Yoonjee C Kao, Winston W.-Y Yuan, Zheng Williams, Basil Gaeke, Samantha Li, S. Kevin Miller, Daniel He, Xingyu |
AuthorAffiliation | Department of Ophthalmology, College of Medicine College of Pharmacy Cincinnati Children’s Hospital Medical Center Department of Chemical & Environment Engineering, College of Engineering and Applied Science |
AuthorAffiliation_xml | – name: Cincinnati Children’s Hospital Medical Center – name: Department of Chemical & Environment Engineering, College of Engineering and Applied Science – name: College of Pharmacy – name: Department of Ophthalmology, College of Medicine |
Author_xml | – sequence: 1 givenname: Xingyu surname: He fullname: He, Xingyu organization: Department of Chemical & Environment Engineering, College of Engineering and Applied Science – sequence: 2 givenname: Zheng orcidid: 0000-0002-2368-0315 surname: Yuan fullname: Yuan, Zheng organization: Department of Chemical & Environment Engineering, College of Engineering and Applied Science – sequence: 3 givenname: Samantha surname: Gaeke fullname: Gaeke, Samantha organization: Department of Chemical & Environment Engineering, College of Engineering and Applied Science – sequence: 4 givenname: Winston W.-Y surname: Kao fullname: Kao, Winston W.-Y organization: Department of Ophthalmology, College of Medicine – sequence: 5 givenname: S. Kevin surname: Li fullname: Li, S. Kevin organization: College of Pharmacy – sequence: 6 givenname: Daniel surname: Miller fullname: Miller, Daniel organization: Department of Ophthalmology, College of Medicine – sequence: 7 givenname: Basil surname: Williams fullname: Williams, Basil organization: Cincinnati Children’s Hospital Medical Center – sequence: 8 givenname: Yoonjee C orcidid: 0000-0003-1454-0326 surname: Park fullname: Park, Yoonjee C email: Yoonjee.park@uc.edu organization: Department of Ophthalmology, College of Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35014495$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kM1Lw0AQxRdRbK29epQcRUjdj2Q3OZZatVBQ_MBj2N1MakuSrbsbof-9q6nixdMMzO895r0TdNiaFhA6I3hCMCVXUjupmgnWmDCWHKAhTQWPeULp4Z99gMbObTDGFGNGsvwYDViKSZLk6RC9LqUDG0-1X39ID2V0bbtVtGi2tWx9VBkbzUzrranrcHuEGgIeeRP5N4gejPNg14F5glUDgTfV92G-g1N0VMnawXg_R-jlZv48u4uX97eL2XQZSyawjzkvIRc0y5RilSapYqyEhGdZzrGQJVU544JqrgjRPBckFSJLCFCaMiVAKzZCF73v1pr3DpwvmrXTUIf3wXSuoDwkJongaUAnPaqtcc5CVWztupF2VxBcfPVZ9H0W-z6D4Hzv3akGyl_8p70AXPZAEBYb09k2RP3P7RMO5n_j |
CitedBy_id | crossref_primary_10_2147_IDR_S398227 crossref_primary_10_3390_gels9070526 crossref_primary_10_3390_ijms242115599 crossref_primary_10_1007_s10570_023_05070_6 crossref_primary_10_1007_s11095_021_03141_6 crossref_primary_10_1021_acsanm_2c03167 crossref_primary_10_1016_j_colsurfa_2021_126778 crossref_primary_10_1039_D2BM01621D crossref_primary_10_1016_j_addr_2022_114395 |
Cites_doi | 10.1021/acsabm.0c00027 10.1021/acs.langmuir.0c00215 10.1111/aos.12020 10.1016/S0376-7388(00)80265-3 10.1016/j.jconrel.2011.10.006 10.1002/jps.2600690305 10.1167/iovs.16-21334 10.1023/A:1016318423563 10.1016/j.preteyeres.2016.12.001 10.1021/acs.jpca.9b02566 10.1364/JOSAA.24.001250 10.1001/jama.2019.12618 10.1136/bmjophth-2019-000293 10.1016/S0006-3495(89)82788-2 10.1186/s40662-015-0026-2 10.3109/02713683.2010.513089 10.1080/00986448308940064 10.1186/s40662-016-0063-5 10.1517/17425247.5.9.1039 10.1167/iovs.07-1335 10.1007/s00417-008-0975-4 10.1002/jps.2600521210 |
ContentType | Journal Article |
Copyright | 2021 American
Chemical Society |
Copyright_xml | – notice: 2021 American Chemical Society |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1021/acsabm.0c01334 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
EISSN | 2576-6422 |
EndPage | 1469 |
ExternalDocumentID | 10_1021_acsabm_0c01334 35014495 b450424038 |
Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCATS NIH HHS grantid: KL2 TR001426 |
GroupedDBID | ABUCX ACS ALMA_UNASSIGNED_HOLDINGS EBS VF5 VG9 53G ABFRP ABQRX AHGAQ BAANH CGR CUPRZ CUY CVF ECM EIF GGK NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a370t-66de97288bb3fc15b33de46889607ad2b93672c6b11c6971577841e2253b7ecb3 |
IEDL.DBID | ACS |
ISSN | 2576-6422 |
IngestDate | Fri Aug 16 20:36:09 EDT 2024 Fri Aug 23 01:46:43 EDT 2024 Thu May 23 23:39:29 EDT 2024 Wed Feb 17 03:12:55 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | triggered drug release multiple releases posterior eye diseases long-term drug delivery drug delivery laser-triggered drug delivery dose-controllable implant |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a370t-66de97288bb3fc15b33de46889607ad2b93672c6b11c6971577841e2253b7ecb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-2368-0315 0000-0003-1454-0326 |
OpenAccessLink | https://doi.org/10.1101/2020.06.17.111641 |
PMID | 35014495 |
PQID | 2618914765 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2618914765 crossref_primary_10_1021_acsabm_0c01334 pubmed_primary_35014495 acs_journals_10_1021_acsabm_0c01334 |
ProviderPackageCode | ACS VG9 ABUCX VF5 |
PublicationCentury | 2000 |
PublicationDate | 20210215 2021-02-15 |
PublicationDateYYYYMMDD | 2021-02-15 |
PublicationDate_xml | – month: 02 year: 2021 text: 20210215 day: 15 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | ACS applied bio materials |
PublicationTitleAlternate | ACS Appl. Bio Mater |
PublicationYear | 2021 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref6/cit6 ref3/cit3 ref27/cit27 ref18/cit18 ref11/cit11 ref25/cit25 ref16/cit16 ref23/cit23 ref14/cit14 ref8/cit8 ref5/cit5 ref2/cit2 ref20/cit20 ref17/cit17 ref10/cit10 ref26/cit26 ref19/cit19 ref21/cit21 ref15/cit15 Haghjou N. (ref7/cit7) 2011; 6 ref22/cit22 ref13/cit13 ref4/cit4 ref1/cit1 ref24/cit24 Peppas N. A. (ref12/cit12) 1985; 60 |
References_xml | – ident: ref3/cit3 doi: 10.1021/acsabm.0c00027 – ident: ref26/cit26 doi: 10.1021/acs.langmuir.0c00215 – ident: ref6/cit6 doi: 10.1111/aos.12020 – ident: ref14/cit14 – ident: ref11/cit11 doi: 10.1016/S0376-7388(00)80265-3 – ident: ref20/cit20 doi: 10.1016/j.jconrel.2011.10.006 – ident: ref24/cit24 doi: 10.1002/jps.2600690305 – ident: ref15/cit15 doi: 10.1167/iovs.16-21334 – volume: 60 start-page: 110 year: 1985 ident: ref12/cit12 publication-title: Pharm. Acta Helv. contributor: fullname: Peppas N. A. – ident: ref22/cit22 doi: 10.1023/A:1016318423563 – ident: ref4/cit4 doi: 10.1016/j.preteyeres.2016.12.001 – ident: ref25/cit25 doi: 10.1021/acs.jpca.9b02566 – ident: ref27/cit27 doi: 10.1364/JOSAA.24.001250 – ident: ref10/cit10 – ident: ref9/cit9 doi: 10.1001/jama.2019.12618 – ident: ref18/cit18 doi: 10.1136/bmjophth-2019-000293 – ident: ref21/cit21 doi: 10.1016/S0006-3495(89)82788-2 – ident: ref8/cit8 – volume: 6 start-page: 317 year: 2011 ident: ref7/cit7 publication-title: J. Ophthalmic Vision Res. contributor: fullname: Haghjou N. – ident: ref1/cit1 doi: 10.1186/s40662-015-0026-2 – ident: ref19/cit19 doi: 10.3109/02713683.2010.513089 – ident: ref23/cit23 doi: 10.1080/00986448308940064 – ident: ref2/cit2 doi: 10.1186/s40662-016-0063-5 – ident: ref5/cit5 doi: 10.1517/17425247.5.9.1039 – ident: ref16/cit16 doi: 10.1167/iovs.07-1335 – ident: ref17/cit17 doi: 10.1007/s00417-008-0975-4 – ident: ref13/cit13 doi: 10.1002/jps.2600521210 |
SSID | ssj0002003189 |
Score | 2.2467604 |
Snippet | To treat chronic posterior eye diseases, frequent intravitreal injections or sustained-release drug implants are the current standard of care.... |
SourceID | proquest crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1461 |
SubjectTerms | Animals Carbocyanines Drug Implants Drug Liberation Fluorescent Dyes Lasers Methotrexate - administration & dosage Methotrexate - pharmacokinetics Rabbits |
Title | Laser-Activated Drug Implant for Controlled Release to the Posterior Segment of the Eye |
URI | http://dx.doi.org/10.1021/acsabm.0c01334 https://www.ncbi.nlm.nih.gov/pubmed/35014495 https://search.proquest.com/docview/2618914765 |
Volume | 4 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV07T8MwELagLCw8xKu8ZAQSU0rsOLYzVgVUIWCgINiinOMwAClq0gF-PWenLQKEYPbJsu6h-853-o6QI12IsMDU7agQTSDA2gBkJgNWaKlEDCA8xcbVtezfiYuH-OHzv-N7B5-zk8xUGbx0QoNgJRLzZIG78UEHgnqD2W8K987psK4D0AGCaj5laPxxhctDpvqah34Blz7JnC83jEeV5yZ0syVPnXENHfP-k7nxz_evkKUJ0qTdxjVWyZwt18j9JWatUdA1fquZzenpaPxIHUUwapgigKW9Znb9Gc9uMCWhOK2HFGEidXt90V9RZmAf3aciHRb-4OzNrpO787PbXj-Y7FYIskiFdSBlbhPFtQaICsNiiKLcCqk1VjQqyzkkkVTcSGDMyESxWLkGpcXoj0BZA9EGaZXD0m4RCjznChQrDEKFLOE6TAo0PAiAjFut2uQQdZBOYqNKfdubs7RRTDpRTJscT-2RvjZEG79KHkzNlWIsuAZHVtrhuEqxGtQJE0rGbbLZ2HF2l2-gYjW4_a_X7JBF7oZX3OaXeJe06tHY7iH6qGHfO94HinfR1g |
link.rule.ids | 315,786,790,2782,27109,27957,27958,57093,57143 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB5RONALD5WWbXm4AolTlrXj2M4RLaClXVDFQ3CLMo7DAditNtlD-fWMnd1FBSHBNR5Zk_E4843H-QZg15SyU1Lo9lSINpLoXIQqVxEvjdIyQZSBYuP0TPWu5K-b5GYO9qf_wpASFc1UhSL-M7sA36dnOT60O5YwSyw_wUKiKRn3WKh7MTtUEcFHPeT1ODoibC2mRI2vpvDhyFb_h6M3MGaINcfL8GemZbhictce19i2jy8IHD_wGiuwNMGd7KBxlFWYc4MvcN2nGDaKDmzoceYKdjga3zJPGEz2ZgRnWbe5yX5PY-cUoEic1UNGoJH5Lr_kvSRz4W79ESMblmHg6J9bg6vjo8tuL5p0WojyWHfqSKnCpVoYgxiXlicYx4WTyhjKb3ReCExjpYVVyLlVqeaJ9uVKR9-CGLWzGH-F-cFw4NaBoSiERs1LS8AhT4XppCW5AUrEXDijW7BDNsgmO6XKQhFc8KwxTDYxTAv2psuS_W1oN96U_DldtYx2hi935AM3HFcZ5YYm5VKrpAXfmuWczRXKqZQbfn-XNtuw2Ls87Wf9k7PfP-Cz8NdafE-YZAPm69HYbRIuqXEr-OITqlDaQQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA4-QLz4wNf6jCh46rpJ0yQ9yuriG_GB3konTfeg7sq2e9Bf7yTtLqgIem1CmE5mMl8yyTeE7OtctHIM3Y4K0QQCrA1ApjJguZZKRADCU2xcXcvTB3H-FD3V77jdWxgUosCRCp_Ed179luU1wwA7xO8pvDZbBnFLKCbJdOSqdzs81L4bH6xwb6cO9josHSC-5iOyxh9DuJBkiq8h6Rec6eNNZ57cjyX110yem8MSmubjG4njP39lgczV-JMeVQazSCZsb4k8XmIsGwRHxtc6sxk9Hgy71BEHo94pwlrarm60v2DbLQYq7E7LPkXwSF21X7Ri7HNnu-6okfZz33DybpfJQ-fkvn0a1BUXgjRUrTKQMrOx4loDhLlhEYRhZoXUGvc5Ks04xKFU3EhgzMhYsUi5tKXFNSEEZQ2EK2Sq1-_ZNUKBZ1yBYrlBAJHGXLfiHM0BBEDKrVYNsoc6SGqPKRKfDOcsqRST1IppkIPR1CRvFf3Grz13RzOXoIe4tEfas_1hkeAeUcdMKBk1yGo1peOxfFoV94jrf5Jmh8zcHHeSy7Priw0yy93tFlcaJtokU-VgaLcQnpSw7c3xE9ZD3Ls |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Laser-Activated+Drug+Implant+for+Controlled+Release+to+the+Posterior+Segment+of+the+Eye&rft.jtitle=ACS+applied+bio+materials&rft.au=He%2C+Xingyu&rft.au=Yuan%2C+Zheng&rft.au=Gaeke%2C+Samantha&rft.au=Kao%2C+Winston+W-Y&rft.date=2021-02-15&rft.eissn=2576-6422&rft.volume=4&rft.issue=2&rft.spage=1461&rft_id=info:doi/10.1021%2Facsabm.0c01334&rft_id=info%3Apmid%2F35014495&rft.externalDocID=35014495 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2576-6422&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2576-6422&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2576-6422&client=summon |